A novel lpxc inhibitor with pan-resistant pseudomonas and burkholderia activity.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93022C00061
- Awardee
-
Revagenix Inc. UEI D98QFZUPFXJ9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $28,167,401
Award facts
- Opportunity
-
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases Pre-Solicitation · PHS20211 · Posted Feb 8, 2021
- Contract value 100% obligated
- $28,167,401.00 Current and potential, with all options
- Completion date 74% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 30 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Mateo, CA 94401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $327,156 | |
| Change Order | $9,957,070 | |
| Funding Only Action | $1,813,440 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,810,788 | |
| Exercise an Option | $2,712,924 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $6,747,098 | |
| Other Administrative Action | $0 | |
| Original award | $4,798,925 |
Show all 13
About this award
The National Institute of Allergy and Infectious Diseases awarded a $28.17 million definitive contract to Revagenix Inc. for development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity on September 22, 2022, under a cost-plus-fixed-fee arrangement with no set-aside.
The originating Broad Agency Announcement, posted February 8, 2021, sought proposals across three research areas: advanced vaccine development, therapeutic product development, and sequencing-based diagnostics, all aimed at countermeasures against biothreat agents and antimicrobial-resistant infections. This award falls within the therapeutic development research area, which carried an estimated total funding envelope of up to $11 million. Place of performance is San Mateo, California. The contract extends through April 25, 2028.
Government-invoiced labor has grown across the contract term. FY2024 reflects 2.0 FTEs and 4,115 contractor hours at a derived blended rate of $798.43 per hour (inclusive of 20% subcontracted hours). FY2023 invoiced $2.4 million across 2.3 FTEs and 4,851 hours at $490.16 per hour. The year-over-year rise in per-hour rates reflects both inflation and shifts in labor mix.
Quick answers
Who was awarded contract 75N93022C00061?
75N93022C00061 was awarded to Revagenix Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 22, 2022.
How much is contract 75N93022C00061 worth?
The government has obligated $28,167,401 on 75N93022C00061.
Was contract 75N93022C00061 competed?
The extent of competition for 75N93022C00061 was full and open competition. The government received 30 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award